Three-year experience with alendronate treatment in postmenopausal osteoporotic japanese women with or without renal dysfunction

A retrospective study

Jun Iwamoto, Yoshihiro Sato, Mitsuyoshi Uzawa, Tsuyoshi Takeda, Hideo Matsumoto

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background and Objective: Chronic kidney disease is associated with an increased risk of fragility fractures. A retrospective study was conducted to compare outcomes after 3 years of alendronate treatment in postmenopausal osteoporotic Japanese women with or without renal dysfunction (RD). Methods: One hundred and thirty-five postmenopausal osteoporotic Japanese women (mean age at baseline: 68 years) who had been treated with alendronate in our outpatient clinic for more than 3 years were analysed. The lumbar spine bone mineral density (BMD) of patients was measured using dual energy x-ray absorptiometry, and urinary levels of cross-linked N-terminal telopeptides of type I collagen (NTX) and serum levels of alkaline phosphatase (ALP) were monitored during the 3-year treatment period. The incidence of osteoporotic fractures was also assessed. Results: Twenty-six women had RD with an estimated glomerular filtration rate (eGFR) of 60mL/min/1.73m2. The urinary NTX and serum ALP levels significantly decreased and the lumbar spine BMD significantly increased, compared with the baseline values, in a manner that was similar among women with or without RD. However, the incidence of non-vertebral fractures, but not that of vertebral fractures, was significantly higher among women with RD than among women without RD. Conclusions: Alendronate treatment appeared to have a similar effect on surrogate markers in postmenopausal osteoporotic Japanese women with or without RD. However, further studies are needed to confirm that RD may increase the risk of non-vertebral fractures in patients treated with alendronate.

Original languageEnglish
Pages (from-to)133-142
Number of pages10
JournalDrugs and Aging
Volume29
Issue number2
DOIs
Publication statusPublished - 2012

Fingerprint

Alendronate
Retrospective Studies
Kidney
Bone Density
Therapeutics
Alkaline Phosphatase
Spine
Osteoporotic Fractures
Incidence
Ambulatory Care Facilities
Serum
Glomerular Filtration Rate
Chronic Renal Insufficiency
Biomarkers
X-Rays

Keywords

  • Alendronic-acid
  • Elderly
  • Kidney-disorders
  • Postmenopausal-osteoporosis.

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Geriatrics and Gerontology

Cite this

Three-year experience with alendronate treatment in postmenopausal osteoporotic japanese women with or without renal dysfunction : A retrospective study. / Iwamoto, Jun; Sato, Yoshihiro; Uzawa, Mitsuyoshi; Takeda, Tsuyoshi; Matsumoto, Hideo.

In: Drugs and Aging, Vol. 29, No. 2, 2012, p. 133-142.

Research output: Contribution to journalArticle

Iwamoto, Jun ; Sato, Yoshihiro ; Uzawa, Mitsuyoshi ; Takeda, Tsuyoshi ; Matsumoto, Hideo. / Three-year experience with alendronate treatment in postmenopausal osteoporotic japanese women with or without renal dysfunction : A retrospective study. In: Drugs and Aging. 2012 ; Vol. 29, No. 2. pp. 133-142.
@article{4636dfca30ad4ffa96ef7c1435baeeac,
title = "Three-year experience with alendronate treatment in postmenopausal osteoporotic japanese women with or without renal dysfunction: A retrospective study",
abstract = "Background and Objective: Chronic kidney disease is associated with an increased risk of fragility fractures. A retrospective study was conducted to compare outcomes after 3 years of alendronate treatment in postmenopausal osteoporotic Japanese women with or without renal dysfunction (RD). Methods: One hundred and thirty-five postmenopausal osteoporotic Japanese women (mean age at baseline: 68 years) who had been treated with alendronate in our outpatient clinic for more than 3 years were analysed. The lumbar spine bone mineral density (BMD) of patients was measured using dual energy x-ray absorptiometry, and urinary levels of cross-linked N-terminal telopeptides of type I collagen (NTX) and serum levels of alkaline phosphatase (ALP) were monitored during the 3-year treatment period. The incidence of osteoporotic fractures was also assessed. Results: Twenty-six women had RD with an estimated glomerular filtration rate (eGFR) of 60mL/min/1.73m2. The urinary NTX and serum ALP levels significantly decreased and the lumbar spine BMD significantly increased, compared with the baseline values, in a manner that was similar among women with or without RD. However, the incidence of non-vertebral fractures, but not that of vertebral fractures, was significantly higher among women with RD than among women without RD. Conclusions: Alendronate treatment appeared to have a similar effect on surrogate markers in postmenopausal osteoporotic Japanese women with or without RD. However, further studies are needed to confirm that RD may increase the risk of non-vertebral fractures in patients treated with alendronate.",
keywords = "Alendronic-acid, Elderly, Kidney-disorders, Postmenopausal-osteoporosis.",
author = "Jun Iwamoto and Yoshihiro Sato and Mitsuyoshi Uzawa and Tsuyoshi Takeda and Hideo Matsumoto",
year = "2012",
doi = "10.2165/11598440-000000000-00000",
language = "English",
volume = "29",
pages = "133--142",
journal = "Drugs and Aging",
issn = "1170-229X",
publisher = "Adis International Ltd",
number = "2",

}

TY - JOUR

T1 - Three-year experience with alendronate treatment in postmenopausal osteoporotic japanese women with or without renal dysfunction

T2 - A retrospective study

AU - Iwamoto, Jun

AU - Sato, Yoshihiro

AU - Uzawa, Mitsuyoshi

AU - Takeda, Tsuyoshi

AU - Matsumoto, Hideo

PY - 2012

Y1 - 2012

N2 - Background and Objective: Chronic kidney disease is associated with an increased risk of fragility fractures. A retrospective study was conducted to compare outcomes after 3 years of alendronate treatment in postmenopausal osteoporotic Japanese women with or without renal dysfunction (RD). Methods: One hundred and thirty-five postmenopausal osteoporotic Japanese women (mean age at baseline: 68 years) who had been treated with alendronate in our outpatient clinic for more than 3 years were analysed. The lumbar spine bone mineral density (BMD) of patients was measured using dual energy x-ray absorptiometry, and urinary levels of cross-linked N-terminal telopeptides of type I collagen (NTX) and serum levels of alkaline phosphatase (ALP) were monitored during the 3-year treatment period. The incidence of osteoporotic fractures was also assessed. Results: Twenty-six women had RD with an estimated glomerular filtration rate (eGFR) of 60mL/min/1.73m2. The urinary NTX and serum ALP levels significantly decreased and the lumbar spine BMD significantly increased, compared with the baseline values, in a manner that was similar among women with or without RD. However, the incidence of non-vertebral fractures, but not that of vertebral fractures, was significantly higher among women with RD than among women without RD. Conclusions: Alendronate treatment appeared to have a similar effect on surrogate markers in postmenopausal osteoporotic Japanese women with or without RD. However, further studies are needed to confirm that RD may increase the risk of non-vertebral fractures in patients treated with alendronate.

AB - Background and Objective: Chronic kidney disease is associated with an increased risk of fragility fractures. A retrospective study was conducted to compare outcomes after 3 years of alendronate treatment in postmenopausal osteoporotic Japanese women with or without renal dysfunction (RD). Methods: One hundred and thirty-five postmenopausal osteoporotic Japanese women (mean age at baseline: 68 years) who had been treated with alendronate in our outpatient clinic for more than 3 years were analysed. The lumbar spine bone mineral density (BMD) of patients was measured using dual energy x-ray absorptiometry, and urinary levels of cross-linked N-terminal telopeptides of type I collagen (NTX) and serum levels of alkaline phosphatase (ALP) were monitored during the 3-year treatment period. The incidence of osteoporotic fractures was also assessed. Results: Twenty-six women had RD with an estimated glomerular filtration rate (eGFR) of 60mL/min/1.73m2. The urinary NTX and serum ALP levels significantly decreased and the lumbar spine BMD significantly increased, compared with the baseline values, in a manner that was similar among women with or without RD. However, the incidence of non-vertebral fractures, but not that of vertebral fractures, was significantly higher among women with RD than among women without RD. Conclusions: Alendronate treatment appeared to have a similar effect on surrogate markers in postmenopausal osteoporotic Japanese women with or without RD. However, further studies are needed to confirm that RD may increase the risk of non-vertebral fractures in patients treated with alendronate.

KW - Alendronic-acid

KW - Elderly

KW - Kidney-disorders

KW - Postmenopausal-osteoporosis.

UR - http://www.scopus.com/inward/record.url?scp=84856269292&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856269292&partnerID=8YFLogxK

U2 - 10.2165/11598440-000000000-00000

DO - 10.2165/11598440-000000000-00000

M3 - Article

VL - 29

SP - 133

EP - 142

JO - Drugs and Aging

JF - Drugs and Aging

SN - 1170-229X

IS - 2

ER -